They measured the serum levels of P1NP, CTX, IL-6, and osteocalcin in the blood of 164 pre-treatment stage I-III breast cancer patients to explore the relationship between these markers and bone metastasis and overall survival. The gene discussed is IL6; the disease is breast carcinoma.